Brexit: Advising Companies To Prepare For Only The Worst Case Scenario Is Premature, Says BIA

The European Medicines Agency has issued figures on the number of UK-based sponsors of orphan medicines, and qualified persons for pharmacovigilance – both of which will be affected when the UK leaves the EU. However, UK BioIndustry Association thinks advising companies on changes they will have to make may be premature as it is yet to be decided what role, if any, the UK will have in the EU medicines network following Brexit.